Meeting
2023 ASCO Genitourinary Cancers Symposium
Automated analysis of FDG-PET/CT imaging to monitor heterogeneous disease response in metastatic castration-resistant prostate cancer.
Authors
Ethan Barnett
Memorial Sloan Kettering Cancer Center, New York, NY
Ethan Barnett , Sungmin Woo , Timothy G. Perk , Rajkumar Munian-Govindan , Ojaswita Lokre , Ria N Gajar , Tatiana Erazo , Emily Carbone , Michael J. Morris , Hebert Alberto Vargas , Howard I. Scher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 251)
DOI
10.1200/JCO.2023.41.6_suppl.251
Abstract #
251
Poster Bd #
F19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Frederic Pouliot
Poster
2021 Genitourinary Cancers Symposium
Combining molecular and functional imaging in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Vincenza Conteduca
Poster
2015 Genitourinary Cancers Symposium
Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.
First Author: Aseem Anand
Poster
2024 ASCO Genitourinary Cancers Symposium
Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.
First Author: David Kersting